·Confidence 90%
Moderna Stock Jumps 90% on Phase 3 mRNA Cancer Vaccine Success
Moderna's stock surged over 90% in premarket trading following the successful Phase 3 trial of its mRNA cancer vaccine, signaling a potential breakthrough in
MRNA ↑ Very strong